IPO - Cue Biopharma, Inc.

Form Type: 8-K

Filing Date: 2025-04-15

Corporate Action: Ipo

Type: New

Accession Number: 000119312525081592

Filing Summary: On April 14, 2025, Cue Biopharma, Inc. entered into an underwriting agreement for a public offering. The offering includes 13,530,780 shares of common stock and accompanying warrants, as well as pre-funded warrants for 11,469,216 shares. The combined offering price per share is set at $0.79 and $0.789 for pre-funded warrants. The estimated net proceeds from the offering are approximately $18.0 million. The offering is expected to close around April 16, 2025, pending customary conditions.

Form Type: 424B5

Filing Date: 2025-04-14

Corporate Action: Ipo

Type: New

Accession Number: 000119312525080293

Filing Summary: Cue Biopharma, Inc. is offering shares of its common stock along with accompanying common stock warrants and pre-funded warrants. This offering aims to raise capital, with terms including an upfront payment of $12 million from a collaboration agreement with Boehringer Ingelheim. The common stock sale is designed to fund advancements in autoimmune programs and general corporate purposes. The company has insufficient cash reserves to continue operations past late 2025, raising concerns about its ability to remain viable without additional financing. The common stock is listed on NASDAQ under the symbol 'CUE', and the last reported sale price was $0.7661 per share.